Drug Interaction Report

Sulfinpyrazone and Lecanemab-Irmb Injection: Interaction Details

A pharmacist-reviewed analysis of the Sulfinpyrazone and Lecanemab-Irmb Injection interaction: the documented clinical effects, severity rating, onset, mechanism, and management considerations, with cited references throughout.

AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature

Sulfinpyrazone

No brand names on record
+

Lecanemab-Irmb Injection

Leqembi Leqembi®
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by
Dr. Brian Staiger, PharmD, BCPS
Updated Aug 8, 2026
Editorial policy · Data sources
LinkedIn
Interaction severity
Moderate
Can be significant — usually manageable with monitoring.
How we grade severity & evidence

Severity levels

  • Contraindicated: These should generally not be used together.
  • Major: Potentially serious — often needs a change or close monitoring.
  • Moderate: Can be significant — usually manageable with monitoring.
  • Minor: Usually limited clinical impact.

Evidence grades

  • Established: Well documented — supported by controlled studies or strong clinical data.
  • Probable: Good supporting evidence, though not definitively proven.
  • Suspected: Some evidence suggests this interaction, but it is not well established.
  • Possible: Limited or conflicting evidence; the interaction may occur.
  • Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Of 69 documented Sulfinpyrazone interactions, 16 are rated moderate — including this one.
Onset
unspecified
Evidence
theoretical
Severity
Moderate

What happens

An increased risk of amyloid related imaging abnormalities or intracerebral hemorrhage

Interaction Deep Dive

Concomitant use of lecanemab-irmb with an antiplatelet agent may increase the risk of amyloid related imaging abnormalities (ARIA) or intracerebral hemorrhage. Concomitant use of lecanemab-irmb with an anticoagulant alone or combined with an antiplatelet medication had an incidence of intracerebral hemorrhage of 2.5% (2/79 patients). Exercise caution when considering the use of lecanemab-irmb in patients with factors that indicate an increased risk for intracerebral hemorrhage, or patients with findings on MRI that are suggestive of cerebral amyloid angiopathy. Exert additional caution with concomitant use of lecanemab-irmb and antithrombotics as it may increase the risk of ARIA or intracerebral hemorrhage, because amyloid related imaging abnormalities with edema (ARIA-E) can cause focal neurologic deficits that can mimic an ischemic stroke2. In clinical trials of lecanemab-irmb, participants were able to continue or initiate aspirin therapy. Lecanemab-irmb treatment may be considered in patients on standard doses of aspirin or other antiplatelet agents, if other criteria for therapy are met 1.

Why it happens (mechanism)

Additive effects on bleeding

Literature reports

1 report — tap to read

a) Concomitant use of lecanemab-irmb with an anticoagulant alone or combined with an antiplatelet medication had an incidence of intracerebral hemorrhage of 2.5% (2/79 patients) 2.

Common questions

Can I take Sulfinpyrazone and Lecanemab-Irmb Injection together?

An increased risk of amyloid related imaging abnormalities or intracerebral hemorrhage Always confirm with your pharmacist or prescriber before making any change.

How serious is the Sulfinpyrazone and Lecanemab-Irmb Injection interaction?

It is rated moderate. Can be significant — usually manageable with monitoring.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.

Questions for your pharmacist

  • Does my dose of Sulfinpyrazone or Lecanemab-Irmb Injection need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there anything you'd monitor while I'm on both?

References (2)

  1. Cummings J, Apostolova L, Rabinovici GD, et al: Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis 2023; 10(3):362-377. PubMed
  2. Product Information: LEQEMBI(R) intravenous injection, lecanemab-irmb intravenous injection. Eisai Inc (per FDA), Nutley, NJ, 2025. DailyMed
Was this write-up helpful?
Sulfinpyrazone

Keep reading about Sulfinpyrazone

All Sulfinpyrazone interactions (69)
Also serious with: Abrocitinib Defibrotide Injection Pegloticase Injection Fondaparinux
Lecanemab-Irmb Injection

Keep reading about Lecanemab-Irmb Injection

All Lecanemab-Irmb Injection interactions (51) Lecanemab-Irmb Injection drug information
Also serious with: Acenocoumarol Alteplase, Recombinant Anistreplase Apixaban
Beyond drug–drug

These medications also interact with supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

Sulfinpyrazone + Activated Charcoal Coffee Charcoal European Mandrake Glucomannan Guar Gum Gum Arabic Inosine Niacin + 11 more

major · moderate · minor — check everything you take with our drug–supplement interaction checker.

Check another combination

Our instant two-drug interaction checker is almost here.

Coming soon

The instant two-drug checker is on its way.

In the meantime, browse the directory below to look up any drug and see its documented interactions.

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.